Eli Lilly Backs Trump's Move to Align International Drug Prices

Eli Lilly has taken an unusual public stance. In a statement issued on August 14, 2025, the company expressed support for the Trump administration’s effort to rebalance pharmaceutical costs by aligning drug prices across developed countries. A key part of this strategy involves raising prices in markets like Europe and the UK to help make U.S. drug prices more affordable in comparison.

Lilly emphasized that this approach promotes fairness by “more fairly sharing the costs of breakthrough medical research across developed countries.” The company noted that lowering U.S. prices requires that governments and health systems abroad pay more. Lilly has already intensified efforts to align prices across developed nations, and it plans to roll out necessary pricing adjustments by September 1, all while pledging continued access for patients.

A prominent example is the UK, where Lilly agreed to increase the list price of Mounjaro, its type 2 diabetes and weight-loss medication, by up to 170%. These changes apply to private market prices; patients obtaining the drug through the National Health Service will maintain access at current costs.

The company also reiterated its firm opposition to pharmaceutical tariffs. Lilly warned that broad tariffs could raise costs, restrict access, and undermine American leadership in innovation—particularly given its ongoing investments in U.S.-based biopharma research and manufacturing.

Underlying Lilly’s position is a broader critique of the U.S. healthcare system. The company highlighted structural problems such as cross subsidies, abuse of government programs like 340B, and heavy insurance cost-sharing, all of which contribute to inflated U.S. drug prices and complicate meaningful reform.

In essence, Lilly’s support for international price alignment is tied to maintaining U.S. access and promoting affordability—but it also serves as a reminder that the path toward drug pricing reform will need to address deep systemic issues.

G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com